Month: January 2024

PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel derivatives of MDMA (MDXX class molecules), is proud to announce that it has received approval to move its PharmAla-1 (P1) molecule through the US Patent and Trademark Office (USPTO) Patent Prosecution Highway pathway based on the positive Patent Cooperation Treaty (PCT) initial office action previously announced by PharmAla. “The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that...

Expects to exceed revised 2023 revenue guidance with fourth quarter 2023 revenue from continuing operations1 of more than $57M with at least 63% year-over-year revenue growth for exome and genome test revenue Reduced fourth quarter 2023 cash burn 51% year-over-year and 21% sequentially Ending December 31, 2023 cash position of at least $131 million Reiterating the path to profitability in 2025 STAMFORD, Conn., Jan. 08, 2024 (GLOBE NEWSWIRE) — GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported preliminary financial results for the fourth quarter and full year of 2023. “We had an incredibly strong fourth quarter as we continued to drive utilization of our industry-leading exome and genome products, improve our average reimbursement rate,...

Dallas, Texas, Jan. 08, 2024 (GLOBE NEWSWIRE) — Nubia Brand International Corp. (the “Company” or “Nubia”), announced today that the conditions to closing the business combination (the “Business Combination”) between the Company and Honeycomb Battery Company (“Honeycomb”), as described in the definitive proxy statement initially filed by Nubia with the SEC on November 8, 2023 (the “Proxy Statement”), have not yet been satisfied and the Business Combination has not closed. The parties are working together to expeditiously satisfy such closing conditions, including obtaining the approval of Nasdaq to list the post-combination company’s common stock following the closing of the Business Combination. There can be no assurance that the Business Combination will be consummated within the time period required by Nubia’s governing documents....

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) —Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin. Covadonga Pañeda, Ph.D., the Company’s Chief Operating Officer, will give a presentation at the conference...

NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) — Roadzen Inc. (Nasdaq: RDZN), a global pioneer in AI-driven insurance and mobility solutions, today announced the appointment of Jean-Noël Gallardo as its new Chief Financial Officer. Mr. Gallardo brings over two decades of experience in financial planning and analysis, treasury management, compliance, fundraising, and M&A, making him an integral addition to the Roadzen leadership team. With his extensive experience in insurtech, brokerage, and claims administration throughout the US and EU, Mr. Gallardo is ideally positioned to propel Roadzen’s continued expansion. He will play a crucial role in enhancing Roadzen’s financial and operational playbook, overseeing investor and analyst engagement, and steering strategic financial initiatives. Most recently, Mr. Gallardo was the...

Aspocomp Group Plc, Stock Exchange Release, January 8, 2024, at 3:30 p.m. Aspocomp Group Plc changes the composition of its Management Team as of January 8, 2024. Member of the Management Team, Chief Operating Officer, and Deputy CEO Antti Ojala has been appointed Chief Commercial Officer as of January 8, 2024. Mr. Ojala will also continue as Deputy CEO. Pekka Holopainen has been appointed Chief Operating Officer, and member of the Aspocomp Management Team as of January 8, 2024. Mr. Holopainen has been working at Aspocomp since 2014, and the most recently he has held the position of Supply Chain Manager. Ari Beilinson leaves his position as Vice President, Sales and Marketing, and member of the Management Team, on January 8, 2024. ”I would like to thank Ari Beilinson warmly for his contribution as Aspocomp’s VP, Sales and Marketing,...

MetaWorks Also Begins Introducing Its AI-Powered Chatbot, ECHO to Healthcare Professionals, Schools and Educational Institutions Fairfield, CA., Jan. 08, 2024 (GLOBE NEWSWIRE) — MetaWorks Platforms, Inc. (“MetaWorks” or the “Company”), (OTCQB: MWRK), an award-winning Web3 company that owns, operates, and develops Web3 platforms, is thrilled to announce the launch of StockHolder.ai. StockHolder.ai will serve as the primary destination for the AI-Powered investor relations & chatbot business launched by MetaWorks in December. MetaWorks has begun rolling out a full AI-Powered investor relations offering that now has the ability to ingest a company’s news and stock information daily and in near real time and use AI to generate video press releases, content and more. MetaWorks President Scott Gallagher commented,...

Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple indications Marker provides updates supporting the clinical benefits of MT-401 in patients with measurable residual disease (MRD) HOUSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) — Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study...